Integrated Genome-Wide Methylation and Expression Analyses Reveal Key Regulators in Osteosarcoma

Area of Science:

• Oncology
• Genetics
• Bioinformatics

Background:

• Osteosarcoma (OS) is a prevalent bone tumor in adolescents with a poor prognosis.
• Aberrant DNA methylation is implicated in cancer development and progression, serving as potential prognostic biomarkers.

Purpose of the Study:

• To identify OS-specific methylated genes using integrated bioinformatics analysis.
• To understand the biological processes and signaling pathways affected by these methylation changes.
• To evaluate the association of dysregulated methylated genes with patient survival and metastasis-free time.

Main Methods:

• Integrated analysis of GSE97529 and GSE42572 gene expression datasets.
• Bioinformatics analysis to identify differentially methylated genes in OS.
• KEGG pathway analysis to determine associated signaling pathways.
• Analysis of R2 datasets to correlate gene dysregulation with metastasis-free survival.

Main Results:

• Identified 18 downregulated and 52 upregulated hypomethylation genes in OS.
• OS-specific methylated genes are involved in chemical synaptic transmission, transcription, drug response, and immune response.
• Associated pathways include Hippo, cAMP calcium, MAPK, and Wnt signaling.
• Dysregulation of genes like CBLN4, ANKMY1, and GZMB correlates with metastasis-free survival in OS patients.

Conclusions:

• This study provides insights into the molecular mechanisms of osteosarcoma progression.
• Identified novel OS-specific methylated genes that may serve as prognostic biomarkers.
• Understanding DNA methylation in OS can lead to improved diagnostic and therapeutic strategies.